The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*
Open accessAbstract
Summary: There is an increasing use of monoclonal antibodies in the treatment of haematological malignancies. Alemtuzumab (Campath‐1H; Ilex Pharmaceuticals, San Antonio, TX, USA) is a monoclonal antibody reactive with the CD52 antigen used as first and second line therapy for two types of lymphoproliferative disorders: chronic lymphocytic leukaemia (CLL), and T‐cell lymphomas [both peripheral (PTCL) and cutaneous (CTCL)]. With alemtuzumab therapy, viral, bacterial and fungal infectious complications are frequent, and may be life threatening. An understanding of the patients at highest risk and duration of risk are important in developing recommendations for empirical management, antimicrobial prophylaxis and targeted surveillance. This review discusses the infection risks associated with these lymphoproliferative disorders and their treatment, and provide detailed recommendations for screening and prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369
Lundin, J., Porwit-MacDonald, A., Rossmann, E. D., Karlsson, C., Edman, P., Rezvany, M. R., Kimby, E., Österborg, A., & Mellstedt, H. (2004) · Leukemia · doi:10.1038/sj.leu.2403258 · Cited by 118
Cited by
Coiffier, B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Fredriksen, H., van Oers, M. H. J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111781 · Cited by 387
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Ljungman, P., de la Camara, R., Cordonnier, C., Einsele, H., Engelhard, D., Reusser, P., Styczynski, J., Ward, K., & Leukemia, F. T. E. C. O. I. I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.162 · Cited by 291
Cooley, L., Dendle, C., Wolf, J., Teh, B. W., Chen, S. C., Boutlis, C., & Thursky, K. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12599 · Cited by 228
Self-citation
Metadata
- Authors
- Thursky, K. A., Worth, L. J., Seymour, J. F., Miles Prince, H., & Slavin, M. A.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2005-11-25
- Volume
- 132
- Issue
- 1
- Pages
- 3-12
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2084366804
- Cited by
- 190
- References
- 2
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. https://app.cochat.ai/papers/10.1111/j.1365-2141.2005.05789.x
- The paper
- Thursky, K. A., Worth, L. J., Seymour, J. F., Miles Prince, H., & Slavin, M. A. (2006). Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2005.05789.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.